Skip to content
Subscriber Only

Primecap Odyssey Outperforms on 40-Fold Gain in Pharmacyclics

The $6.8 billion Primecap Odyssey Aggressive Growth Fund beat 99 percent of rivals in performance over the past five years. A single stock, Pharmacyclics Inc., played a big role in that success.

Pharmacyclics, which agreed to be acquired today for $21 billion, has risen more than 40-fold in the past five years, a period in which it was consistently one of the fund’s top positions. The stock contributed about 15 percent of the fund’s total gain over that period, according to data compiled by Bloomberg.